14-day Premium Trial Subscription Try For FreeTry Free
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ: EXEL) today announced that Takeda Pharmaceutical Company Limited (Takeda), its partner responsible for the clinical development and commercial

Got $50? 4 Smart Stocks to Buy Into Right Now

05:51am, Friday, 27'th Nov 2020
You don't need to start with a fortune to build wealth on Wall Street.
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that members of the company's management team will participate in fireside chats at the following virtual investor confe
Exelixis, Inc. (EXEL) CEO Michael Morrissey Presents at Stifel 2020 Virtual Healthcare Conference (Transcript)
Exelixis' (EXEL) CEO Mike Morrissey on Q3 2020 Results - Earnings Call Transcript
Exelixis (EXEL) delivered earnings and revenue surprises of -100.00% and 7.05%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Is Exelixis, Inc. (NASDAQ:EXEL) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top investors,

Is Exelixis Stock a Buy?

06:32am, Tuesday, 03'rd Nov 2020
The pharmaceutical company is moving beyond its longtime reliance on a single cancer drug, but what will those changes mean for shareholders?
The election won't impact the ability of these great companies to deliver for their shareholders.

Better Buy: Illumina vs. Exelixis

06:57am, Wednesday, 28'th Oct 2020
These two stocks have very different methods of generating returns.
Exelixis' (EXEL) applications for Cabometyx in combination with Opdivo for the treatment of RCC has been accepted by the FDA.
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ: EXEL) today announced that Takeda Pharmaceutical Company Limited (Takeda), its partner responsible for the clinical development and commercial
IBM Retirement Fund raised its position in shares of Exelixis, Inc. (NASDAQ:EXEL) by 29.3% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commissio
Exelixis, Inc. (Nasdaq: EXEL) announced today that its third quarter 2020 financial results will be released on Thursday, November 5, 2020 after the m
In a report released yesterday, Jay Olson from Oppenheimer assigned a Buy rating to Exelixis (EXEL – Research Report), with
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE